Hemogenyx Pharmaceuticals innovates with intranasal mRNA delivery for airborne viral infections

Hemogenyx Pharmaceuticals plc (LSE: HEMO), a clinical-stage biopharmaceutical group, has made a significant stride in the realm of biotechnology with its recent in vivo demonstration of the Chimeric Bait Receptor (CBR) delivery via intranasal route using messenger RNA (mRNA). This innovative approach marks a potential game-changer for the treatment of airborne viral infections, showcasing a novel method of administering therapeutics that combines ease of use with long shelf life at ambient temperatures.

Breakthrough in Biotech: Intranasal mRNA Delivery

The CBR platform technology, under development by Hemogenyx Pharmaceuticals, is designed to harness the power of the body’s innate immune cells, such as macrophages, to eradicate viruses and certain malignant cells. The groundbreaking in vivo demonstration revealed that mRNA encoding a CBR-based therapeutic could be mixed with a polymer and solvent at room temperature to create nanoparticles. These nanoparticles are capable of delivering the CBR-coding mRNA into the upper respiratory tract and lungs of small animals, where immune cells begin producing CBR molecules to act as defenders against airborne infections.

Revolutionizing Treatment: Hemogenyx Pharmaceuticals Unveils Intranasal mRNA Therapeutics

Accelerating R&D Through AI and In-house mRNA Synthesis

Hemogenyx Pharmaceuticals’ utilization of Artificial Intelligence (AI) and in-house synthesis of mRNA has significantly accelerated its research and development efforts. AI tools enable the efficient triaging of CBR construct variants, selecting those with the highest potential for success. Concurrently, in-house mRNA synthesis allows for the swift assembly of CBR constructs, streamlining the development process.

A Vision for Off-the-Shelf Viral Infection Prevention

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, highlighted the significance of this advancement, stating, “This major breakthrough in the method of delivery of our CBR demonstrates that it could potentially be used as an off-the-shelf prevention and/or treatment for viral infections.” The intranasal delivery method not only promises cost efficiency but also ease of administration, making it an ideal solution for protecting the civilian population and aiding in biodefense.